NCT07614048 — Providence Health & Services cancer immunotherapy trial
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS
Registry record
| Registry ID | NCT07614048 ↗ |
|---|---|
| Lead sponsor | Providence Health & Services |
| Collaborators | — |
| Phase | — |
| Status | Available |
| Indication | PDAC - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer |
| Enrollment | — |
| Start date | — |
| Primary completion | — |
| Last registry update | 23 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07614048), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07614048?
NCT07614048 (Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Providence Health & Services.
Is NCT07614048 recruiting?
As of the 2026-07-23 registry update, NCT07614048 is listed as "Available". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07614048?
The lead sponsor is Providence Health & Services.
What condition does NCT07614048 study?
The registered conditions are PDAC - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer. Primary completion is listed as not listed.
Are results available for NCT07614048?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07614048.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.